Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, the first in a yearlong series on Key Decisions in HIV Care, Daniel R. Kuritzkes, MD, and Chloe Orkin, MBChB, FRCP, MD, discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy. Following their dialogue, the faculty field questions from healthcare professionals.
Daniel R. Kuritzkes, MD
Chief, Division of Infectious
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Clinical Care Options (CCO) expert audio: Drs Chloe Orkin and Babafemi Taiwo discuss new HIV data presented at IDWeek and HIV Glasgow 2022
Dr Neha Pandit discusses barriers and solutions to PrEP uptake in key patient populations in this commentary from Clinical Care Options (CCO)
Dr Monica Gandhi discusses key advances in HIV treatment over the past year, from Clinical Care Options (CCO)
A patient advocate discusses the importance of community-led HIV treatment and prevention, from Clinical Care Options (CCO)